These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21033700)

  • 1. A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells.
    Wu N; Wu XW; Agama K; Pommier Y; Du J; Li D; Gu LQ; Huang ZS; An LK
    Biochemistry; 2010 Nov; 49(47):10131-6. PubMed ID: 21033700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors.
    Yu LM; Zhang XR; Li XB; Yang Y; Wei HY; He XX; Gu LQ; Huang ZS; Pommier Y; An LK
    Eur J Med Chem; 2015 Aug; 101():525-33. PubMed ID: 26188908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors.
    Yu Q; Yang H; Zhu TW; Yu LM; Chen JW; Gu LQ; Huang ZS; An LK
    Eur J Med Chem; 2018 May; 152():195-207. PubMed ID: 29705710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
    BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
    Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
    Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiproliferative activity of indolizinophthalazine-5,12-dione derivatives, DNA topoisomerase IB inhibitors.
    Shen DQ; Wu ZP; Wu XW; An ZY; Bu XZ; Gu LQ; Huang ZS; An LK
    Eur J Med Chem; 2010 Sep; 45(9):3938-42. PubMed ID: 20638158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor.
    Yu Q; Chen Y; Yang H; Zhang HL; Agama K; Pommier Y; An LK
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):818-822. PubMed ID: 30907213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis.
    Tian QT; Ding CY; Song SS; Wang YQ; Zhang A; Miao ZH
    Biochem Pharmacol; 2018 Aug; 154():255-264. PubMed ID: 29753750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
    Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
    PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
    Majumdar P; Bathula C; Basu SM; Das SK; Agarwal R; Hati S; Singh A; Sen S; Das BB
    Eur J Med Chem; 2015 Sep; 102():540-51. PubMed ID: 26312433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Camptothecin Derivative 3j Inhibits Nsclc Proliferation Via Induction of Cell Cycle Arrest By Topo I-Mediated DNA Damage.
    Liu Y; Zhang J; Feng S; Zhao T; Li Z; Wang L; Wang P; Du H; Yuan S; Sun L
    Anticancer Agents Med Chem; 2019; 19(3):365-374. PubMed ID: 30523769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors.
    Seol Y; Zhang H; Agama K; Lorence N; Pommier Y; Neuman KC
    Mol Cancer Ther; 2015 Nov; 14(11):2552-9. PubMed ID: 26351326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
    Lian C; Cao S; Zeng W; Li Y; Su J; Li J; Zhao S; Wu L; Tao J; Zhou J; Chen X; Peng C
    Biochem Pharmacol; 2020 Jan; 171():113716. PubMed ID: 31751535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel securinine derivatives as topoisomerase I based antitumor agents.
    Hou W; Wang ZY; Peng CK; Lin J; Liu X; Chang YQ; Xu J; Jiang RW; Lin H; Sun PH; Chen WM
    Eur J Med Chem; 2016 Oct; 122():149-163. PubMed ID: 27344492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors.
    Dong G; Fang Y; Liu Y; Liu N; Wu S; Zhang W; Sheng C
    Bioorg Med Chem Lett; 2017 May; 27(9):1929-1933. PubMed ID: 28351590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipin functions in the protection against topoisomerase I inhibitor.
    Hosono Y; Abe T; Higuchi M; Kajii K; Sakuraba S; Tada S; Enomoto T; Seki M
    J Biol Chem; 2014 Apr; 289(16):11374-11384. PubMed ID: 24573676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.
    Arakawa Y; Ozaki K; Okawa Y; Yamada H
    Oncol Rep; 2013 Sep; 30(3):1053-8. PubMed ID: 23836376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
    Tomicic MT; Kaina B
    Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Topoisomerase I mutations are associated with resistance to camptothecin.
    Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
    Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase I inhibitors: Challenges, progress and the road ahead.
    Talukdar A; Kundu B; Sarkar D; Goon S; Mondal MA
    Eur J Med Chem; 2022 Jun; 236():114304. PubMed ID: 35413618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.